BNGOBionano Genomics, Inc.

Nasdaq bionanogenomics.com


$ 1.16 $ 0.07 (6.42 %)    

Thursday, 28-Mar-2024 12:30:04 EDT
QQQ $ 444.34 $ -0.36 (-0.08 %)
DIA $ 397.56 $ -0.62 (-0.16 %)
SPY $ 523.26 $ 0.01 (0 %)
TLT $ 94.86 $ 0.38 (0.4 %)
GLD $ 206.00 $ 1.04 (0.51 %)
$ 1.09
$ 1.11
$ 1.15 x 1,200
$ 1.16 x 1,700
$ 1.10 - $ 1.16
$ 1.00 - $ 11.80
1,742,588
na
37.22M
$ 2.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-05-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-04-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-23-2021 12-31-2020 10-K
14 11-13-2020 09-30-2020 10-Q
15 08-13-2020 06-30-2020 10-Q
16 06-18-2020 03-31-2020 10-Q
17 03-10-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-14-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bionano-announces-publication-of-a-breast-cancer-study-showing-that-the-number-of-svs-detected-with-ogm-may-be-related-to-prognosis-tumor-progression-and-chemotherapy-resistance

Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary b...

 scotiabank-maintains-sector-outperform-on-bionano-genomics-lowers-price-target-to-6

Scotiabank analyst Sung Ji Nam maintains Bionano Genomics (NASDAQ:BNGO) with a Sector Outperform and lowers the price target...

 bionano-genomics-sees-q1-revenue-825m-875m-vs-969m-est-fy24-revenue-37m-41m-vs-4717m-est

2024 OutlookWe remain hyper focused on our mission of transforming the way the world sees the genome. To that end we want to hi...

 bionano-genomics-q4-sales-10721m-beat-10585m-estimate

Bionano Genomics (NASDAQ:BNGO) reported quarterly sales of $10.721 million which beat the analyst consensus estimate of $10.585...

 earnings-scheduled-for-march-5-2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

 bionano-publishes-interim-readout-from-second-phase-of-clinical-trial-analyzing-optical-genome-mapping-as-standard-of-care-for-prenatal-testing

Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome m...

 bionano-announces-full-commercial-release-of-the-stratys-system-for-high-throughput-optical-genome-mapping

Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial rele...

 bionano-announces-peer-reviewed-publication-from-its-clinical-study-designed-to-support-ogm-as-part-of-standard-of-care-in-genetic-disease-testing

Peer-reviewed publication from Broeckel, et al. describes the second phase of a multisite evaluation of optical genome mapping ...

 bionano-reports-preliminary-q4-and-fy23-results-sees-q4-revenue-104m-107m-vs-1054m-est-fy23-revenue-358m-361m-vs-3594m-est-achieved-all-full-year-2023-elevate-milestones

Preliminary Q4 2023 revenue expected to be between $10.4 and $10.7 million, which would represent an estimated increase of 27% ...

 bionano-laboratories-announced-the-publication-of-the-first-framework-paper-for-the-clinical-adoption-and-implementation-of-the-optical-genome-mapping-workflow-for-hematological-malignancy-applications

Framework was co-authored by an international consortium made up of 18 cancer researchersPublication includes researchers' ...

 bionano-announces-publication-of-largest-prospective-prenatal-study-comparing-ogm-to-chromosomal-microarray-analysis-and-karyotyping

Key findings from prospective evaluation of 200 prenatal samples:   Optical genome mapping (OGM) detected pathogenic structu...

 bionano-genomics-announces-cancers-journal-publishes-special-issue-dedicated-to-ogms-impact-on-hematological-malignancy-research

Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated ...

 bionano-laboratories-announces-publication-of-the-analytical-validation-of-its-ogm-based-laboratory-developed-test-for-hematological-malignancies-and-additional-multi-site-technical-evaluation-of-ogm

Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed ...

 bionano-announces-presentations-featuring-ogm-utility-across-blood-cancer-research-at-the-american-society-of-hematology-annual-meeting

A platform presentation will feature Dr. Enze Liu from the Indiana University School of Medicine sharing findings from a study ...

Core News & Articles

https://thebearcave.substack.com/p/problems-at-axos-financial-ax?utm_campaign

 bionano-announces-presentation-of-ogm-utility-across-key-research-applications-at-the-association-for-molecular-pathology-annual-meeting

A corporate workshop session will feature Dr. Alka Chaubey, Bionano's chief medical officer, Dr. Panieh Terraf from Memoria...

 maxim-group-downgrades-bionano-genomics-to-hold

Maxim Group analyst Jason McCarthy downgrades Bionano Genomics (NASDAQ:BNGO) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION